SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Natco Pharma receives approval for generic version of ledipasvir+sofosbuvir tablets in India

15 Dec 2015 Evaluate

Natco Pharma has received approval for the generic version of ledipasvir+sofosbuvir combination from Drugs Controller General (India). The company plans to launch this combination drug immediately, under its brand name Hepcinat LP, and through its strategic partners in India. Ledipasvir+Sofosbuvir is a two-drug fixed-dose combination product that contains 90 mg of ledipasvir and 400 mg of sofosbuvir in a single tablet, and sold globally by Gilead Sciences, Inc., under its brand HARVONI. It is indicated for the treatment of chronic hepatitis C (CHC) genotype 1 infection in adults. This single-tablet regimen is the first of its kind to offer significantly higher cure rates in Genotype-1 CHC infection compared to conventional therapies.

The company will price its generic medicine, Hepcinat LP, at an MRP of Rs 25,000 for a bottle of 28 tablets. The company was the first licensed company to launch the generic version of this combination drug earlier in Nepal. The company had signed a non-exclusive licensing agreement with Gilead Sciences earlier in 2015 to manufacture and sell generic versions of its chronic hepatitis C medicines, including generic version of HARVONI, in 100 other developing countries in addition to India.

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.

Natco Pharma Share Price

1154.55 -19.45 (-1.66%)
11-May-2026 09:37 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1842.30
Dr. Reddys Lab 1278.10
Cipla 1336.80
Zydus Lifesciences 932.30
Lupin 2273.05
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×